3.4.22.B70: SENP1 peptidase
This is an abbreviated version!
For detailed information about SENP1 peptidase, go to the full flat file.
Reaction
The enzyme catalyzes two essential functions in the SUMO pathway: processing of full-length SUMO-1, SUMO-2 and SUMO-3 to their mature forms and deconjugation of SUMO-1, SUMO-2 and SUMO-3 from targeted proteins. Deconjugates SUMO-1 from homeodomain-interacting protein kinase 2. Deconjugates SUMO-1 from histone deacetylase 1, which decreases its transcriptional repression activity. Cleavage of Gly97-/-His98 bond in the SUMO-1 precursor with release of the propeptide His-Ser-Thr-Val. Cleavage of Gly93-/-Val94 bond in the SUMO-2 precursor with release of the propeptide Val94-Thyr. Cleavage of the Gly92-/-Val93 in the SUMO-3 precursor with release of the propeptide Pro-Glu-Ser-Ser-Leu-Ala-Gly-His-Ser-Phe.
=
Synonyms
C13orf22l, SENP, SENP1, sentrin-specific protease 1, sentrin/SUMO-specific protease 1, small ubiquitin-like modifier protein-specific protease 1, small ubiquitin-related modifier-specific isopeptidase, SUMO isopeptidase, SUMO protease, SUMO protein-specific protease 1, SUMO-specific isopeptidase, SUMO-specific protease, SUMO-specific protease 1, ubiquitin-specific protease-like 1, USPL1
ECTree
Application
Application on EC 3.4.22.B70 - SENP1 peptidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
diagnostics
-
enzyme SENP1 is an important cancer metastasis-related molecule and may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients
diagnostics
-
SENP1 may serve as a potential diagnostic and therapeutic target of pancreatic ductal adenocarcinoma
drug development
-
SENP1 is a potential therapeutic target for the treatment of prostate cancers
drug development
-
SENP1 is an essential gene and is a potential target for developing therapeutic agents for cancer
drug development
-
the enzyme is a drug target for development of small molecule drugs against prostate cancer
medicine
-
diagnostic value of measuring the urinary content of SENP1 mRNAs for detection of tumor recurrence
medicine
-
SENP1 is overexpressed in most of colon cancer tissues. SENP1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors
medicine
SENP1 overexpression induces transformation of the normal prostate gland and gradually facilitates the onset of high-grade prostatic intraepithelial neoplasiade. SUMOylation plays a critical role in prostate pathogenesis through induction of HIF1alpha-dependent angiogenesis and enhanced cell proliferation
medicine
-
SENP1, can transform normal prostate epithelia to a dysplasic state and directly modulate several oncogenic pathways in prostate cells, including AR, c-Jun, and Cyclin D1
medicine
SENP1 expression has strong prognostic impact in a molecularly defined subset of cancers. In the subgroup of ERG positive, PTEN undeleted cancers, the prognostic role of SENP1 expression is independent of the preoperative PSA level, tumor stage, Gleason grade, and the status of the resection
medicine
the expression of SENP1 is positively correlated with the malignant grades of astrocytoma. The NF-kappaB and Akt signaling pathways in glioblastoma multiforme tissues are activated. Knock-down of endogenous SENP1 promotes cell apoptosis. Downregulation of SENP1 expression can inhibit the phosphorylation of IkappaBalpha and Akt, and also the expression of its downstream regulation factors Bcl-xL and cyclinD1